Logo image of ABOS

ACUMEN PHARMACEUTICALS INC (ABOS) Stock Fundamental Analysis

NASDAQ:ABOS - Nasdaq - US00509G2093 - Common Stock - Currency: USD

1.42  +0.02 (+1.43%)

After market: 1.35 -0.07 (-4.93%)

Fundamental Rating

1

We assign a fundamental rating of 1 out of 10 to ABOS. ABOS was compared to 551 industry peers in the Biotechnology industry. ABOS has a bad profitability rating. Also its financial health evaluation is rather negative. ABOS is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

1

1. Profitability

1.1 Basic Checks

In the past year ABOS has reported negative net income.
In the past year ABOS has reported a negative cash flow from operations.
In the past 5 years ABOS always reported negative net income.
In the past 5 years ABOS always reported negative operating cash flow.
ABOS Yearly Net Income VS EBIT VS OCF VS FCFABOS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 -20M -40M -60M -80M -100M

1.2 Ratios

ABOS has a Return On Assets (-57.08%) which is comparable to the rest of the industry.
ABOS has a Return On Equity of -75.05%. This is comparable to the rest of the industry: ABOS outperforms 52.81% of its industry peers.
Industry RankSector Rank
ROA -57.08%
ROE -75.05%
ROIC N/A
ROA(3y)-27.08%
ROA(5y)-28.29%
ROE(3y)-32.76%
ROE(5y)-32.44%
ROIC(3y)N/A
ROIC(5y)N/A
ABOS Yearly ROA, ROE, ROICABOS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 -20 -40 -60 -80 -100

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for ABOS so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ABOS Yearly Profit, Operating, Gross MarginsABOS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024 -100 -200 -300 -400 -500

3

2. Health

2.1 Basic Checks

The number of shares outstanding for ABOS has been increased compared to 1 year ago.
Compared to 5 years ago, ABOS has more shares outstanding
ABOS has a worse debt/assets ratio than last year.
ABOS Yearly Shares OutstandingABOS Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 20M 40M 60M
ABOS Yearly Total Debt VS Total AssetsABOS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 100M 200M 300M

2.2 Solvency

Based on the Altman-Z score of -2.63, we must say that ABOS is in the distress zone and has some risk of bankruptcy.
With a Altman-Z score value of -2.63, ABOS perfoms like the industry average, outperforming 49.18% of the companies in the same industry.
ABOS has a Debt/Equity ratio of 0.19. This is a healthy value indicating a solid balance between debt and equity.
Looking at the Debt to Equity ratio, with a value of 0.19, ABOS is doing worse than 69.69% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.19
Debt/FCF N/A
Altman-Z -2.63
ROIC/WACCN/A
WACCN/A
ABOS Yearly LT Debt VS Equity VS FCFABOS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 100M 200M

2.3 Liquidity

ABOS has a Current Ratio of 8.02. This indicates that ABOS is financially healthy and has no problem in meeting its short term obligations.
ABOS has a Current ratio of 8.02. This is in the better half of the industry: ABOS outperforms 70.78% of its industry peers.
A Quick Ratio of 8.02 indicates that ABOS has no problem at all paying its short term obligations.
With a decent Quick ratio value of 8.02, ABOS is doing good in the industry, outperforming 71.14% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 8.02
Quick Ratio 8.02
ABOS Yearly Current Assets VS Current LiabilitesABOS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M

0

3. Growth

3.1 Past

The earnings per share for ABOS have decreased strongly by -84.76% in the last year.
EPS 1Y (TTM)-84.76%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-92%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to decrease by -3.90% on average over the next years.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-27.95%
EPS Next 2Y-0.46%
EPS Next 3Y5.76%
EPS Next 5Y-3.9%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
ABOS Yearly Revenue VS EstimatesABOS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2030 2031 2032 50M 100M 150M 200M
ABOS Yearly EPS VS EstimatesABOS Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 1 -1 2 -2 -3

0

4. Valuation

4.1 Price/Earnings Ratio

ABOS reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ABOS. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ABOS Price Earnings VS Forward Price EarningsABOS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ABOS Per share dataABOS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-0.46%
EPS Next 3Y5.76%

0

5. Dividend

5.1 Amount

No dividends for ABOS!.
Industry RankSector Rank
Dividend Yield N/A

ACUMEN PHARMACEUTICALS INC

NASDAQ:ABOS (8/7/2025, 8:09:24 PM)

After market: 1.35 -0.07 (-4.93%)

1.42

+0.02 (+1.43%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-13 2025-05-13/bmo
Earnings (Next)08-18 2025-08-18/bmo
Inst Owners70.41%
Inst Owner Change0.68%
Ins Owners6.03%
Ins Owner Change1.5%
Market Cap86.01M
Analysts87.27
Price Target8.93 (528.87%)
Short Float %2.82%
Short Ratio2.97
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-15.14%
Min EPS beat(2)-26.63%
Max EPS beat(2)-3.65%
EPS beat(4)0
Avg EPS beat(4)-20.91%
Min EPS beat(4)-34.3%
Max EPS beat(4)-3.65%
EPS beat(8)3
Avg EPS beat(8)-6.41%
EPS beat(12)4
Avg EPS beat(12)-5.37%
EPS beat(16)5
Avg EPS beat(16)-19.7%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-4.89%
EPS NQ rev (1m)0%
EPS NQ rev (3m)3.45%
EPS NY rev (1m)-0.94%
EPS NY rev (3m)5.16%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 0.55
P/tB 0.55
EV/EBITDA N/A
EPS(TTM)-1.94
EYN/A
EPS(NY)-1.73
Fwd EYN/A
FCF(TTM)-1.69
FCFYN/A
OCF(TTM)-1.69
OCFYN/A
SpS0
BVpS2.57
TBVpS2.57
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -57.08%
ROE -75.05%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-27.08%
ROA(5y)-28.29%
ROE(3y)-32.76%
ROE(5y)-32.44%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.19
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 46.45%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 8.02
Quick Ratio 8.02
Altman-Z -2.63
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)184.58%
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-84.76%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-92%
EPS Next Y-27.95%
EPS Next 2Y-0.46%
EPS Next 3Y5.76%
EPS Next 5Y-3.9%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-91.24%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-45.28%
EBIT Next 3Y-14.8%
EBIT Next 5YN/A
FCF growth 1Y-175.47%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-176.36%
OCF growth 3YN/A
OCF growth 5YN/A